Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf281 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Gabrielle B Rocque und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, United States. Hauptthemen laut MEDLINE: Quality of Life, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc, USA.
Abstract (Originalsprache)
Importance Patient-reported outcomes are recommended clinical outcome assessments of quality of life (QoL) by patient advocacy groups and regulatory agencies to gain a better understanding of treatment effectiveness, tolerability and safety.
Objectives
In this study, we aimed to enhance and contextualize the interpretation of patient-reported scores on global health status (GHS) and QoL from the EORTC QLQ−C30 questionnaire into more meaningful terms using data from POLARIS. Design, Setting, and Participants Patients ≥ 18 years of age who had a diagnosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced/metastatic breast cancer (ABC/mBC) were enrolled in the prospective, observational, multicenter, real-world POLARIS study.
Intervention
Patients received palbociclib plus endocrine therapy as first-line, second-line or later line of therapy. Main Outcomes and Measures Proportions of patients with “favorable” (numeric scores 5−7) and “unfavorable” (numeric scores ≤ 4) responses were determined at baseline and months 6, 12, and 18.
Results
Between January 2017 and January 2023, 1250 patients were enrolled and received ≥ 1 palbociclib dose. EORTC QLQ−C30 GHS/QoL domain completion rates were 93.4%, 66.5%, 49.5%, and 42.3% at baseline and months 6, 12, and 18, respectively. For Question 29 (GHS), the proportion of patients with a favorable response significantly increased by ∼13% to 69.3% by month 6, which was maintained at month 12 (68.6%) and month 18 (70.0%). For Question 30 (QoL), the proportion of patients with a favorable response significantly increased by ∼9% to 74.5% by month 6, which was maintained at month 12 (75.0%) and month 18 (73.4%). Conclusions and Relevance The proportions of patients with HR+/HER2− ABC/mBC indicating a favorable response on GHS and QoL questions of the EORTC QLQ−C30 increased early on after the start of palbociclib treatment and were preserved through month 18 across the overall study population and most evaluated subgroups. This simple interpretation of GHS and QoL scores is intended to enhance their meaning to benefit patients and other stakeholders. Clinical Trial Registration NCT03280303; registered September 12, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
- Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX 75246, United States.
- Oncology and Hematology, Health Partners Institute, St. Paul, MN 55101, United States.
- Breast Medical Oncology, Saint Luke's Cancer Institute, Kansas City, MO 64111, United States.
- Mid-Illinois Hematology & Oncology Associates Ltd, Normal, IL 61761, United States.
- Hematology and Oncology, Saint Vincent's Birmingham, Birmingham, AL 35205, United States.
ORCID-Profile: Gabrielle B Rocque, Eric Gauthier
Förderung
- Pfizer Inc, USA
Zitieren
APA
Rocque, G. B., Blum, J. L., Ji, Y., Pluard, T., Migas, J., Lakhanpal, S., Jepsen, E., Gauthier, E., Wang, Y., Montelongo, M. Z., Cappelleri, J. C., Chen, C., Karuturi, M. S., & Tripathy, D. (2025). Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf281
Vancouver
Rocque GB, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, et al. Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf281
BibTeX
@article{Rocque2025,
author = {Rocque, Gabrielle B and Blum, Joanne L and Ji, Yan and Pluard, Timothy and Migas, John and Lakhanpal, Shailendra and Jepsen, Erin and Gauthier, Eric and Wang, Yao and Montelongo, Monica Z and Cappelleri, Joseph C and Chen, Connie and Karuturi, Meghan S and Tripathy, Debu},
title = {Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf281}
}
EUVIMED